Trademark: 88926068
Word
MYOFIA
Status
Dead
Status Code
606
Status Date
Monday, May 2, 2022
Serial Number
88926068
Mark Type
4000
Filing Date
Wednesday, May 20, 2020
Published for Opposition
Tuesday, August 4, 2020
Abandoned Date
Monday, May 2, 2022

Trademark Owner History
Allergan Sales, LLC - Owner At Publication

Classifications
5 Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Events
May 2, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
May 2, 2022
Abandonment - No Use Statement Filed
Aug 10, 2021
Notice Of Approval Of Extension Request E-Mailed
Aug 6, 2021
Sou Extension 2 Granted
Aug 6, 2021
Sou Extension 2 Filed
Aug 6, 2021
Teas Extension Received
Mar 11, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 9, 2021
Sou Extension 1 Granted
Mar 9, 2021
Sou Extension 1 Filed
Mar 9, 2021
Teas Extension Received
Sep 29, 2020
Noa E-Mailed - Sou Required From Applicant
Aug 4, 2020
Official Gazette Publication Confirmation E-Mailed
Aug 4, 2020
Published For Opposition
Jul 15, 2020
Notification Of Notice Of Publication E-Mailed
Jul 1, 2020
Approved For Pub - Principal Register
Jun 28, 2020
Assigned To Examiner
Jun 5, 2020
New Application Office Supplied Data Entered In Tram
May 23, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24